Cardiff Oncology (CRDF) Share-based Compensation (2011 - 2026)

Cardiff Oncology has reported Share-based Compensation for 15 years, with the latest figure at $1.3 million in Q4 2025.

• Quarterly Share-based Compensation rose 4.73% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.5 million (up 15.82% YoY) and the FY2025 annual result came in at $9.8 million, up 40.0% from the prior year.
• Share-based Compensation slipped to $1.3 million in Q4 2025 per CRDF's latest filing, from $11.4 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $11.4 million in Q3 2025 and troughed at $268000.0 in Q1 2021.
• A 5-year average of $1.6 million and a median of $1.1 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2024 and 2025: Share-based Compensation declined 25.43% in 2024, then jumped 809.82% in 2025.
• Over 5 years, Share-based Compensation stood at $990000.0 in 2021, then gained by 2.22% to $1.0 million in 2022, then declined by 10.18% to $909000.0 in 2023, then jumped by 32.45% to $1.2 million in 2024, then increased by 4.73% to $1.3 million in 2025.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.3 million, $11.4 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.